E. Gamelin

1.5k total citations
29 papers, 1.2k citations indexed

About

E. Gamelin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, E. Gamelin has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Pathology and Forensic Medicine. Recurrent topics in E. Gamelin's work include Colorectal Cancer Treatments and Studies (15 papers), Cancer Treatment and Pharmacology (8 papers) and Gastric Cancer Management and Outcomes (6 papers). E. Gamelin is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Cancer Treatment and Pharmacology (8 papers) and Gastric Cancer Management and Outcomes (6 papers). E. Gamelin collaborates with scholars based in France, Switzerland and United States. E. Gamelin's co-authors include Thierry André, Aimery de Gramont, Christophe Louvet, Olivier Bouché, Esteban Cvitkovic, Jean‐Yves Douillard, M. Flesch, Emmanuel Achille, Pascal Piedbois and N. Tubiana-Mathieu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Brain Research.

In The Last Decade

E. Gamelin

28 papers receiving 1.1k citations

Peers

E. Gamelin
Costanza Annamaria Lagrasta Italy
Zhiwei Zhou China
Sarah R. McWhinney United States
I. Shchepotin United States
Haitao Zhou China
Nigel C. Bird United Kingdom
Silvia Carpano Italy
Nobuo Ochi Japan
Jian Feng China
Kenji Tsuchihashi Japan
Costanza Annamaria Lagrasta Italy
E. Gamelin
Citations per year, relative to E. Gamelin E. Gamelin (= 1×) peers Costanza Annamaria Lagrasta

Countries citing papers authored by E. Gamelin

Since Specialization
Citations

This map shows the geographic impact of E. Gamelin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Gamelin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Gamelin more than expected).

Fields of papers citing papers by E. Gamelin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Gamelin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Gamelin. The network helps show where E. Gamelin may publish in the future.

Co-authorship network of co-authors of E. Gamelin

This figure shows the co-authorship network connecting the top 25 collaborators of E. Gamelin. A scholar is included among the top collaborators of E. Gamelin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Gamelin. E. Gamelin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lortholary, Alain, Mireille Cossée, E. Gamelin, & F Larra. (2012). Paraneoplastic Syndromes. SpringerReference. 80(3). 177–91. 4 indexed citations
3.
Boisdron‐Celle, M., Alain Morel, & E. Gamelin. (2010). Déficits en dihydropyrimidine déshydrogénase et toxicité aux fluoropyrimidines. Annales de biologie clinique. 68(1). 27–32. 4 indexed citations
4.
Louvet, Christophe, Thierry André, E. Gamelin, et al.. (2010). Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. Journal of Oncology. 2010. 1–7. 4 indexed citations
5.
Ychou, Marc, Jean‐Luc Raoul, Jean‐Yves Douillard, et al.. (2009). A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Annals of Oncology. 20(4). 674–680. 127 indexed citations
6.
Louvet, Christophe, Thierry André, E. Gamelin, et al.. (2007). Antitumour activity of pemetrexed (Pem) and irinotecan (Iri) in second-line metastatic colorectal cancer (MCRC) patients: A multicenter phase II study. Journal of Clinical Oncology. 25(18_suppl). 4103–4103. 2 indexed citations
7.
Nguyen, Suzanne, Christine Rebischung, M. Flesch, et al.. (2006). Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.. PubMed. 93(1). E1–6. 17 indexed citations
8.
André, Thierry, Emmanuel Quinaux, Christophe Louvet, et al.. (2005). Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. Journal of Clinical Oncology. 23(16_suppl). 3522–3522. 13 indexed citations
9.
Roullin, Gaëlle, Laurent Lemaire, Marie‐Claire Venier‐Julienne, et al.. (2004). Influence of 5-Fluorouracil-Loaded Microsphere Formulation on Efficient Rat Glioma Radiosensitization. Pharmaceutical Research. 21(9). 1558–1563. 18 indexed citations
10.
André, Thierry, Philippe Colin, Christophe Louvet, et al.. (2003). Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial. Journal of Clinical Oncology. 21(15). 2896–2903. 185 indexed citations
11.
Louvet, Christophe, Thierry André, Gérard Lledo, et al.. (2002). Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II Study. Journal of Clinical Oncology. 20(6). 1512–1518. 91 indexed citations
12.
Morel, Olivier, et al.. (2001). False-Positive Suspicion of a Thyroid Metastatic Lesion by In-111 Pentetreotide Uptake in a Toxic Nodular Goiter. Clinical Nuclear Medicine. 26(6). 579–581. 2 indexed citations
13.
Meneï, Philippe, Marie‐Claire Venier‐Julienne, E. Gamelin, et al.. (1999). Local and sustained delivery of 5‐fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. Cancer. 86(2). 325–330. 3 indexed citations
14.
15.
Muratet, Jean-Pierre, et al.. (1997). Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.. PubMed. 38(9). 1362–8. 47 indexed citations
16.
Delva, R., E. Gamelin, P. Maillart, et al.. (1997). Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC). European Journal of Cancer. 33. S167–S167. 5 indexed citations
17.
Montero‐Menei, Claudia N., Laurence Sindji, Emmanuel Garcion, et al.. (1996). Early events of the inflammatory reaction induced in rat brain by lipopolysaccharide intracerebral injection: relative contribution of peripheral monocytes and activated microglia. Brain Research. 724(1). 55–66. 61 indexed citations
18.
Dorval, Étienne, Corinne Regimbeau, E. Gamelin, Laurence Picon, & H. Bérard. (1995). [Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].. PubMed. 19(1). 27–30. 6 indexed citations
19.
Louvet, C., Aimery de Gramont, K. Beerblock, et al.. (1995). 557 Hydroxyurea, folinic acid, 5FU bolus and infusion (HLFP regimen) in advanced gastric cancer. European Journal of Cancer. 31. S119–S119. 1 indexed citations
20.
Delva, R., F Pein, Alain Lortholary, et al.. (1993). Métastases osseuses des cancers colorectaux: à propos de huit cas. La Revue de Médecine Interne. 14(4). 223–228. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Costanza Annamaria Lagrasta Breakdown of academic impact, for papers by Zhiwei Zhou Breakdown of academic impact, for papers by Sarah R. McWhinney Breakdown of academic impact, for papers by I. Shchepotin Breakdown of academic impact, for papers by Haitao Zhou Breakdown of academic impact, for papers by Nigel C. Bird Breakdown of academic impact, for papers by Silvia Carpano Breakdown of academic impact, for papers by Nobuo Ochi Breakdown of academic impact, for papers by Jian Feng Breakdown of academic impact, for papers by Kenji Tsuchihashi
Rankless by CCL
2026